The DOI matches its Crossref record; 106 of the 108 references it cites were found in a registry or an index.
Hybrid nanoparticles for combination therapy of cancer
Open accessAbstract
Nanoparticle anticancer drug delivery enhances therapeutic efficacies and reduces side effects by improving pharmacokinetics and biodistributions of the drug payloads in animal models. Despite promising preclinical efficacy results, monotherapy nanomedicines have failed to produce enhanced response rates over conventional chemotherapy in human clinical trials. The discrepancy between preclinical data and clinical outcomes is believed to result from the less pronounced enhanced permeability and retention (EPR) effect in and the heterogeneity of human tumors as well as the intrinsic/acquired drug resistance to monotherapy over the treatment course. To address these issues, recent efforts have been devoted to developing nanocarriers that can efficiently deliver multiple therapeutics with controlled release properties and increased tumor deposition. In ideal scenarios, the drug or therapeutic modality combinations have different mechanisms of action to afford synergistic effects. In this review, we summarize recent progress in designing hybrid nanoparticles for the co-delivery of combination therapies, including multiple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, and chemotherapeutics and radiotherapy. The in vitro and in vivo anticancer effects are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, synthetic tunability enables the creation of smart nanoparticles that can simultaneously serve several therapeutic or imaging goals by co-encapsulating various therapeutic compounds with various release curves.22,23”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications
Gupta, A. K., & Gupta, M. S. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2004.10.012 · Cited by 6,906
Metal–Organic Frameworks for Separations
Li, J.-R., Sculley, J., & Zhou, H.-C. (2012) · Chemical Reviews · doi:10.1021/cr200190s · Cited by 6,323
Cancer Cell Imaging and Photothermal Therapy in the Near-Infrared Region by Using Gold Nanorods
Huang, X., El‐Sayed, I. H., Qian, W. P., & El‐Sayed, M. A. (2006) · Journal of the American Chemical Society · doi:10.1021/ja057254a · Cited by 5,442
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
Hydrogen Storage in Microporous Metal-Organic Frameworks
Rosi, N. L., Eckert, J., Eddaoudi, M., Vodak, D. T., Kim, J., O’Keeffe, M., & Yaghi, O. M. (2003) · Science · doi:10.1126/science.1083440 · Cited by 4,850
In vivo cancer targeting and imaging with semiconductor quantum dots
Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. K., & Nie, S. (2004) · Nature Biotechnology · doi:10.1038/nbt994 · Cited by 4,775
Horcajada, P., Chalati, T., Serre, C., Gillet, B., Sebrié, C., Baâti, T., Eubank, J. F., Heurtaux, D., Clayette, P., Rogez‐Kreuz, C., et al. (2009) · Nature Materials · doi:10.1038/nmat2608 · Cited by 4,270
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Luminescent metal–organic frameworks for chemical sensing and explosive detection
Hu, Z., Deibert, B. J., & Li, J. (2014) · Chemical Society Reviews · doi:10.1039/c4cs00010b · Cited by 4,168
Cited by
Sorted by citations
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B. C., Huang, P., & Chen, X. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,813
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 610
Aggregation-Induced Emission (AIE), Life and Health
Wang, H., Li, Q., Alam, P., Bai, H., Bhalla, V., Bryce, M. R., Cao, M., Chen, C., Chen, S., Chen, X., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c03925 · Cited by 404
Wang, T., Wang, D., Yu, H., Wang, M., Liu, J., Feng, B., Zhou, F., Yin, Q., Zhang, Z., Huang, Y., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b07706 · Cited by 294
Metadata
- Authors
- He, C., Lu, J., & Lin, W.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Lin, Wenbin
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 219
- Pages
- 224-236
- ISSN
- 0168-3659 (ISSN-L)
- PMC
- PMC4656047
- OpenAlex
- W1770290865
- Cited by
- 174
- References
- 108
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 19 · 2023: 13 · 2022: 13 · 2021: 13 · 2020: 16 · 2019: 15 · 2018: 9 · 2017: 20 · 2016: 12
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (U01-CA151455)
- University of Chicago Medicine Comprehensive Cancer Center (P30 CA014599)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- hybrid nanostructures, combination cancer therapy, co-delivery, nanocarriers, drug resistance, enhanced permeability and retention effect, tumor heterogeneity, photodynamic therapy, radiotherapy, chemotherapeutics, biologics, controlled release, synergistic drug delivery
- MeSH terms
- Animals, Antineoplastic Agents, Drug Combinations, Ferric Compounds, Gold, Humans, Neoplasms, Organometallic Compounds, Polymers, Drug Delivery Systems, Organosilicon Compounds, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
